• Experts assess how patent expiry of semaglutide is reshaping GLP-1 pricing and patient access

• DoP again tweaks RPTUAS guidelines to liberalise modalities of implementation

• Trump's 100% tariff on patented drugs and ingredients may have limited impact immediately, say reports

• Permitting large-scale clinical study integrating Ayurveda with modern TB treatment a landmark step: expert